Semaglutide: the literature behind Ozempic, Wegovy, and the research-chemical parallel market.
Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk, marketed as Ozempic (T2DM, 2017), Wegovy (obesity, 2021), and Rybelsus (oral T2DM, 2019). The published clinical trial record is one of the largest for any peptide in modern medicine, and the parallel research-chemical market has become one of the most legally fraught segments of the peptide-vendor industry. Understanding both sides is essential for anyone working in this space.
- 31-amino-acid modified GLP-1(7-37) analog with a fatty-acid (C18 diacid) side chain that binds serum albumin, extending half-life from ~2 min (native GLP-1) to ~165 hours (weekly dosing viable).
- STEP program: eight Phase III trials in obesity. STEP-1 (N=1,961): mean weight loss 14.9% at 68 weeks (2.4 mg/week SC) vs 2.4% placebo.
- SUSTAIN program: Phase III in T2DM. HbA1c reductions of ~1.5–1.8% at once-weekly dosing.
- SELECT trial (2023): cardiovascular outcomes in overweight/obese non-diabetic patients — 20% reduction in MACE (HR 0.80, p<0.001).
- 2023–2024 FDA drug shortage created a large compounded / "research-use" market. 2024 FDA enforcement actions followed. The regulatory picture is active and changing.
- USP released a semaglutide reference standard (2024); compliance-minded buyers should cross-check RUO COAs against the USP monograph.
Mechanism
GLP-1 (glucagon-like peptide-1) is an incretin secreted by L-cells of the small intestine after meals. It binds the GLP-1 receptor (GLP-1R, a class B GPCR) expressed on pancreatic β-cells, brain (hypothalamus, area postrema), GI tract, and heart. GLP-1R activation triggers glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central satiety signaling.
Native GLP-1 has a plasma half-life of ~2 minutes (rapid DPP-4 and neutral endopeptidase degradation). Semaglutide addresses this with three engineering changes: (1) an Aib substitution at position 8 that blocks DPP-4 cleavage; (2) a C18 diacid fatty-acid side chain attached via a γGlu-2xOEG linker at Lys26 that binds serum albumin and slows renal filtration; (3) a K34R point mutation to preserve binding. Net result: a peptide with a ~165-hour plasma half-life, enabling once-weekly subcutaneous dosing.
The STEP program, in numbers
STEP (Semaglutide Treatment Effect in People with obesity) was the pivotal Phase III program for Wegovy. Eight trials total; the headline result is STEP-1 (Wilding et al., NEJM 2021):
- N = 1,961 adults with obesity (BMI ≥30) or overweight with comorbidity.
- Semaglutide 2.4 mg/week SC vs placebo, both with lifestyle intervention, 68 weeks.
- Primary endpoint: mean body-weight change from baseline. Semaglutide −14.9% vs placebo −2.4%.
- ≥5% weight loss: 86.4% vs 31.5%. ≥15% weight loss: 50.5% vs 4.9%.
- Improvements in waist circumference, HbA1c, lipids, systolic BP, and C-reactive protein.
Subsequent STEP trials showed similar effects in adolescents (STEP TEENS), in patients with T2DM (STEP 2, ~10% loss), and with intensive behavioral therapy (STEP 3, ~16% loss).
The SELECT trial — cardiovascular outcomes
SELECT (Lincoff et al., NEJM 2023) randomized 17,604 patients with established cardiovascular disease and overweight/obesity (without diabetes) to semaglutide 2.4 mg/week vs placebo for mean follow-up 39.8 months. Composite primary endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) occurred in 6.5% vs 8.0% (HR 0.80, 95% CI 0.72–0.90, p<0.001). This is a 20% relative reduction in MACE — a first-in-class cardiovascular outcome benefit for an anti-obesity drug in non-diabetic patients.
The research-chemical market — why it's a legal minefield
Semaglutide entered a widely visible supply crunch starting 2022. The FDA declared Ozempic and Wegovy in shortage in 2022, which under section 503A and 503B of the FD&C Act permits compounding pharmacies to compound analogous formulations. A large compounded-semaglutide market emerged — legal in principle, variable in practice.
In parallel, research-chemical vendors began selling semaglutide lyophilized powder for "research use only." Three distinct tiers exist in 2026:
- FDA-approved branded product (Ozempic, Wegovy, Rybelsus). Prescription only. Manufactured by Novo Nordisk under cGMP. Price: ~$900–$1,300/month list.
- Compounded semaglutide from 503A/503B pharmacies. Legal under FDA shortage provisions; quality varies by compounding pharmacy. Once the official shortage was resolved, FDA began enforcement on compounding outside the shortage framework.
- Research-chemical semaglutide. Sold RUO by peptide vendors. Quality varies enormously — COA reliability and sequence verification are major issues.
How to read an RUO semaglutide COA against the USP monograph
The USP (United States Pharmacopeia) released a semaglutide reference standard and draft monograph in 2024. Compliance-minded buyers can cross-check vendor COAs against the monograph's identity, purity, and impurity-profile requirements. Key data points to ask for:
- Identity: HPLC retention time matching USP reference standard ± 2%.
- Primary purity: >98% by RP-HPLC; USP target is ≥99.0% for drug-quality material.
- Related compounds: individual known impurities < 0.5%, total related compounds < 2%.
- Mass-spec confirmation: [M+H]⁺ = 4114 Da ± 0.5.
- Water content: < 6% (Karl Fischer).
- Counterion / salt form: disclosed (typically acetate for RUO).
- Bacterial endotoxins: LAL assay, < 5 EU/mg for any injectable-intent compound.
Research-chemical COAs often provide some but not all of these. The gap between "98% purity by HPLC" and "matches USP monograph" is the practical gap between a research-grade compound and a drug-grade compound.
Safety signals from the approved-drug record
- GI side effects. Nausea (~44% at titration), vomiting, diarrhea. Titration schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg/week over 16+ weeks) exists specifically to mitigate these.
- Pancreatitis. Rare (< 0.5%) but reported across the class. Contraindicated in personal or family history of medullary thyroid carcinoma or MEN-2.
- Gallbladder events. Cholelithiasis rate elevated modestly in STEP trials.
- Euglycemic ketoacidosis. Reported with other GLP-1 analogs; rare with semaglutide but monitored.
- Muscle loss. Weight loss is ~30–40% lean mass in trials. Preservation strategies (resistance training, adequate protein) are relevant to long-term outcomes.
Dosing, as on the approved label
| Week | Wegovy (obesity) dose | Ozempic (T2DM) dose |
|---|---|---|
| 1–4 | 0.25 mg/week SC | 0.25 mg/week SC |
| 5–8 | 0.5 mg/week SC | 0.5 mg/week SC |
| 9–12 | 1.0 mg/week SC | 1.0 mg/week SC (maintenance) |
| 13–16 | 1.7 mg/week SC | (up to 2.0 mg/week) |
| 17+ | 2.4 mg/week SC (maintenance) | — |
Where to read further
- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." N. Engl. J. Med. 2021;384:989–1002. (STEP-1)
- Davies MJ, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." Lancet 2021;397:971–984.
- Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." N. Engl. J. Med. 2023;389:2221–2232. (SELECT)
- Lau J, et al. "Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide." J. Med. Chem. 2015;58(18):7370–80.
- USP. Draft monograph: "Semaglutide." 2024 revision.
- FDA. Wegovy and Ozempic prescribing information, current revisions.